EGFR and non-small cell lung carcinoma: In the context of NSCLC carrying EGFR oncogenic mutations, elevated levels of AXL and GAS6 have been found to confer resistance to EGFR-TKIs (e.g., erlotinib and osimertinib) in certain tumors with mesenchymal-like features.